Rhoen Klinikum AG RHKJF
Morningstar’s Analysis
1-Star Price
PREMIUM
5-Star Price
PREMIUM
Economic Moat
PREMIUM
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here .
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile
Rhoen Klinikum AG provides medical care focused in five key areas: cardiovascular medicine, neuromedicine, oncology, pulmonary diseases, and orthopedic and trauma surgery. The firm operates in three business areas: acute hospitals, medical care centers, and rehabilitation hospitals. The acute hospitals business contributes to the vast majority of the firm's overall revenue. The majority of patients at the firm's acute hospitals and medical care centers are treated on an outpatient basis. Rhoen Klinikum generates the entirety of its revenue in Germany, with the Bavaria and Hesse regions contributing the largest proportions of revenue.
Bad Neustadt a. d. Saale, 97616, Germany